Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07466602) titled 'cfDNA Methylation for Liver Cancer Recurrence Detection' on Feb. 26.

Study Type: Observational

Primary Sponsor: Wuhan Ammunition Life-tech Co., Ltd

Condition: Primary Liver Cancer

Intervention: Diagnostic Test: plasma GNB4 and Riplet genes methylation detection

Recruitment Status: Recruiting

Date of First Enrollment: September 2, 2025

Target Sample Size: 500

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/study/NCT07466602

Published by HT Digital Content Services with permission from Health Daily Digest....